Vanda Pharmaceuticals (VNDA) Tops Q3 EPS by 7c, updates guidance
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $5.43 +1.69%
EPS Growth %: -60.5%
Financial Fact:
Intangible asset amortization: 2.94M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -60.5%
Financial Fact:
Intangible asset amortization: 2.94M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q3 EPS of ($0.09), $0.07 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $47.7 million versus the consensus estimate of $50.75 million.
GUIDANCE:
Vanda Pharmaceuticals sees FY2024 revenue of $190-210 million, versus the consensus of $197.4 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
- JPMorgan Reiterates Overweight Rating on Legrand SA (LR:FP) (LGRDY) and Places on Positive Catalyst Watch
- Computacenter Plc. (CCC:LN) PT Raised to GBP60 at JPMorgan
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
